Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.96 USD | +0.34% | +1.02% | -28.50% |
06-05 | Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target | MT |
05-08 | Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.50% | 89.32M | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+2.18% | 22.67B | |
-10.09% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- RLMD Stock
- News Relmada Therapeutics, Inc.
- Insider Trends: 90-Day Insider Selling Trend Extended at Relmada Therapeutics